Gossamer bio to host webcast to discuss latest seralutinib open-label extension data on december 18, 2023

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced that it will host a public conference call and webcast for investors and analysts on monday, december 18, 2023 at 8:30 am et to discuss the latest seralutinib clinical data from the ongoing torrey phase 2 open-label extension study in pah patients. sera.
GOSS Ratings Summary
GOSS Quant Ranking